Abstract
The use of coronavirus disease 2019 (COVID-19) vaccines will play the major role in helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have resulted in robust humoral responses and protective efficacy in human trials, but efficacy trials excluded individuals with a prior diagnosis of COVID-19. As a result, little is known about how immune responses induced by mRNA vaccines differ in individuals who recovered from COVID-19. Here, we evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19. Consistent with prior studies of mRNA vaccines, we observed robust cytotoxic CD8 + T cell responses in both cohorts after the second dose. Furthermore, SARS-CoV-2–naive individuals had progressive increases in humoral and antigen-specific antibody-secreting cell (ASC) responses after each dose of vaccine, whereas SARS-CoV-2–experienced individuals demonstrated strong humoral and antigen-specific ASC responses to the first dose but these responses were not further enhanced after the second dose of the vaccine at the time points studied. Together, these data highlight the relevance of immunological history for understanding vaccine immune responses and may have implications for personalizing mRNA vaccination regimens used to prevent COVID-19, including for the deployment of booster shots.
【초록키워드】 COVID-19, coronavirus disease, mRNA vaccination, Efficacy, Vaccine, COVID-19 vaccine, immune response, pandemic, Trial, mRNA vaccine, CD8, mRNA vaccines, Cohort, Humoral response, response, trials, T cell response, booster, BNT162b2 mRNA vaccination, Protective, dose, humoral, regimen, second dose, These data, first dose, individual, implication, helping, Prevent, immunological, Cell, highlight, robust, evaluated, demonstrated, excluded, the vaccine, increases in, ASC, diagnosis of COVID-19, 【제목키워드】 immune response, mRNA vaccine, dose, individual, of BNT162b2,